Bayer

EQS-News: Bayer and Aignostics to collaborate on next generation precision oncology

Retrieved on: 
Wednesday, April 10, 2024
Algorithm, Disease, Drug discovery, Intelligence, Partnership, Patient, Hospital, Artificial intelligence, Cancer, Executive Committee, AI, Biology, Bayer, Pathology, Machine learning, Pharmaceutical industry

Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Key Points: 
  • Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.
  • The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies.
  • Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
  • Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.

AskBio Names Mansuo Shannon Chief Scientific Officer

Retrieved on: 
Tuesday, April 9, 2024
Eli Lilly, Alzheimer's disease, Gene editing, Princeton University, MIT, Research, Bayer, Chugai Pharmaceutical Co., Doctor of Philosophy, Samulski, Therapy, Eli Lilly and Company, CSO, Molecular biology, Management

Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company

Key Points: 
  • Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
    Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
    Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that on April 8, 2024, Mansuo Shannon, PhD, was named the company’s next Chief Scientific Officer (CSO).
  • Shannon joins AskBio from Prevail Therapeutics, where she also served as CSO.
  • Reporting to Gustavo Pesquin, Chief Executive Officer (CEO), Shannon will be a member of AskBio’s Executive Leadership Team and head its R&D organization.
  • As part of her role as CSO at AskBio, Shannon will develop and implement the company’s future R&D strategy.

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Retrieved on: 
Monday, April 8, 2024
Retina, Amgen, Organization, Regeneron Pharmaceuticals, Doctor of Pharmacy, Chiron Corporation, Patient, ISTA Pharmaceuticals, Bayer, Shore, AMD, Ophthalmology, Pharmaceutical industry

Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team.

Key Points: 
  • Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team.
  • Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- and post-launch initiatives for medicines in ophthalmology and retinal disease.
  • Over the course of his career, Dr. Han has served in senior leadership positions in medical and scientific affairs at leading biopharmaceutical companies.
  • He joins Opthea from Adverum Biotechnologies, Inc. where he led the development of the Medical Affairs function.

SK hynix announces semiconductor advanced packaging investment in Purdue Research Park

Retrieved on: 
Wednesday, April 3, 2024
CHIPS, Second Continental Congress, HBM, Congress, MediaTek, Federation, Partnership, Technology policy, SK Hynix, Saab, Research, I-65, News, Rolls-Royce, AI, Social responsibility, Semiconductor, Bayer, Silicon, Workforce, ChatGPT, Purdue Research Park, Policy

WEST LAFAYETTE, Ind., April 03, 2024 (GLOBE NEWSWIRE) -- SK hynix Inc. announced Wednesday (April 3) that it plans to invest close to $4 billion to build an advanced packaging fabrication and R&D facility for AI products in the Purdue Research Park.

Key Points: 
  • WEST LAFAYETTE, Ind., April 03, 2024 (GLOBE NEWSWIRE) -- SK hynix Inc. announced Wednesday (April 3) that it plans to invest close to $4 billion to build an advanced packaging fabrication and R&D facility for AI products in the Purdue Research Park.
  • “We are excited to build a state-of-the-art advanced packaging facility in Indiana,” said SK hynix CEO Kwak Noh-Jung.
  • “SK hynix is the global pioneer and dominant market leader in memory chips for AI,” Purdue President Mung Chiang said.
  • This historic announcement is the next step in Purdue University’s persistent pursuit of semiconductor excellence as part of the Purdue Computes initiative.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Retrieved on: 
Tuesday, April 9, 2024
Other Communications, Other Health, Marketing, Communications, General Health, Other Natural Resources, Fitness & Nutrition, Agriculture, Natural Resources, Science, Vitamins, Supplements, Other Science, Health, Research, Medical Supplies, Growth, Philosophy, Business administration, BBDO, Diversity, University, Equity, Walmart, Bayer, Love, P&G, Aspirin, BBA, CMO, Tenneco, Multimedia, Loratadine, Advance Auto Parts, Avivi

Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.

Key Points: 
  • Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.
  • She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer.
  • View the full release here: https://www.businesswire.com/news/home/20240409885941/en/
    “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi.
  • “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi.

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Retrieved on: 
Monday, March 25, 2024
Retina, Research, Gene, Development, IRD, Leber congenital amaurosis, Retinitis pigmentosa, Paratriathlon, Patient, Bayer, Foundation Fighting Blindness, Visual impairment, University, Wilfrid Sellars, Senior, IND, Therapy, IPSC, Usher syndrome, B cell, Pharmaceutical industry

The new cohort will include patients living with IRDs caused by mutations in multiple genes.

Key Points: 
  • The new cohort will include patients living with IRDs caused by mutations in multiple genes.
  • “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
  • OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, Farmer, Gene editing, Entrepreneurship, HT1, Seed, HT2, Net, Bayer, PSR, Breeding, CBUS, WOSR, European Parliament, Agriculture

We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.

Key Points: 
  • We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.
  • This vote was a significant milestone for our entire industry and is a crucial step that will help Cibus usher in the gene editing era."
  • 2 Cibus Powered™ is the internal Cibus trait standard that ensures each Cibus trait meets minimum efficacy and quality assurance commercial requirements.
  • Cibus will host a live webcast, Thursday, March 21, 2024, at 4:30 p.m. Eastern Standard Time to discuss its fourth quarter 2023 financial results and provide a business update.

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

Retrieved on: 
Monday, March 18, 2024
Internal medicine, Circulatory system, Certification, CKPT, FASN, Biotechnology, FACP, Research, University, Nephrology, Society, Marketing, Hematology, Alexion, Bayer, Health, Hypertension, Pharmaceutical industry

WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.

Key Points: 
  • WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.
  • Prior to joining Alexion, he served as Vice President of Medical Affairs for the Cardiovascular and Renal Division of Bayer Pharmaceuticals.
  • “We are pleased to welcome Dr. Sharma to our Board of Directors,” said James F. Oliviero, President and Chief Executive Officer of Checkpoint.
  • “He is a highly accomplished life sciences executive, with leadership experience in many facets of both patient care and the research, development, approval and commercialization of pharmaceutical products.

Bayer and Aignostics to collaborate on next generation precision oncology

Retrieved on: 
Thursday, March 14, 2024
Algorithm, Disease, Drug discovery, Intelligence, Partnership, Patient, Hospital, Artificial intelligence, Cancer, Executive Committee, AI, Biology, Bayer, Pathology, Machine learning, Pharmaceutical industry

BERLIN, March 14, 2024 (GLOBE NEWSWIRE) -- Bayer and Aignostics GmbH today announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.

Key Points: 
  • The partners will co-create a novel target identification platform that leverages Aignostics’ technology and proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies.
  • Under the terms of the agreement, the companies will collaborate on multiple discovery programs and initiate at least two target identification programs.
  • Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
  • Aignostics will receive an upfront payment and is eligible to receive success-based milestone payments and royalties on any commercialized therapies that result from the collaboration.